Navigation Links
ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study
Date:4/15/2008

al comparison of both the areas under the curve (AUC) and maximum plasma concentrations (Cmax) and was determined based on federal regulations and FDA guidance regarding bioequivalence studies. AUC is a measure of the total amount of the drug circulating in the body over time. Cmax is the maximum concentration of the drug measured in the blood at any given time. If the upper and lower bounds of the AUC ratio's and the Cmax ratio's 90% confidence interval ranged from 0.80 to 1.25, ANX-530 and Navelbine were considered to have equivalent pharmacokinetics. The results of a clinical study are actually estimates of what might be expected if the treatment were to be given to the entire population of interest. Confidence intervals indicate the precision of such an estimate. Pursuant to the study's protocol and statistical analysis plan, data from all 31 patients who received both study drugs were included in the analysis.

A summary of the pharmacokinetic results is set forth in the following table:

Pharmacokinetic Acceptable Range

Parameters ANX-530 Navelbine 90% Confidence Interval

Cmax (ng/mL) 227 223 87-123% 80-125%

AUClast (hrng/mL) 758 717 99-112% 80-125%

AUCinf (hrng/mL) 810 719 100-112% 80-125%

Cmax: Maximum plasma concentration

AUClast: Area under the plasma concentration time curve from time zero to

the last time point

AUCinf: Area under the plasma concentration time curve from time zero to

infinity

Both ANX-530 and Navelbine were administered via a 10 minute intravenous injection at a dose of 30 mg/m2. Blood samples for pharmacokinetic analysis were collected prior to the initiation of patient dosing, and, at 10, 20, and 40 minutes after patient dosing, as well as at 1, 3, 6, 24, 48, 72, and 144 hours aft
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
2. Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology
3. Elekta Demonstrates Commitment to Stereotactic Innovation at EANS
4. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
5. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
6. Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
7. ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
8. Magnifi Group Demonstrates Industrys First Interactive Educational Program (IEP) for Spine Fellows
9. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
10. Job-related stress: NIST demonstrates fatigue effects in silicon
11. USGI Medical Demonstrates First System for Gastrotomy Closure in NOTES
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Neogen Corporation (Nasdaq: ... future forecasts of its potential revenue from new rodenticide ... to investors and analysts on July 22, 2014, Neogen,s ... analysts regarding this research. "It was my ... about the potential of a new type of rodenticide, ...
(Date:7/24/2014)... 24, 2014  Spherix Incorporated (SPEX) -- an intellectual ... of intellectual property, today announced that the Company will ... 30, 2014 on Monday, August 18, 2014 for shareholders. ... ET on Monday, August 18, 2014 to discuss the ... company,s CEO, Anthony Hayes . Following ...
(Date:7/23/2014)... Emirates (UAE) (PRWEB) July 23, 2014 ... recently announced that its biobanking project, Provia ... Ph.D. to its growing Advisory Board. Scott Wolf ... pleased to have Dr. Vaught onboard with Provia’s ever-expanding ... and expertise that Provia’s management team brings to this ...
(Date:7/23/2014)... July 23, 2014 /PRNewswire-iReach/ -- Think Drinks are a ... the long term. They are the first functional focus ... energy as an alternative to the temporary fix associated ... Indiegogo on July 29, 2014, with hopes to raise ... Photo - http://photos.prnewswire.com/prnh/20140723/129697 ...
Breaking Biology Technology:Neogen comments on SenesTech 2Spherix Schedules Shareholder Update Call 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2
... changes and further organizational ... consolidation ... Paul LaViolette to retire ... that President and Chief Executive,Officer Jim Tobin will be extending his tenure at the Company. The ...
... Patients Worldwide, FERNDALE, Michigan and NESS ZIONA, ... Ltd. announced today that the two,companies executed a ... foam for the treatment of atopic dermatitis and,eczema., ... development of,non-steroidal foam which is designed to help ...
... Periodontal Inflammation and ... Gene-Environment Interactions, WALTHAM, Mass., June 3 ... Dr. Kenneth Kornman, Chief,Scientific Officer, will present at the 13th ... Ljubljana, Slovenia on the,genetic and environmental factors that control inflammation ...
Cached Biology Technology:Boston Scientific Announces CEO Jim Tobin to Extend Tenure 2Boston Scientific Announces CEO Jim Tobin to Extend Tenure 3Boston Scientific Announces CEO Jim Tobin to Extend Tenure 4Boston Scientific Announces CEO Jim Tobin to Extend Tenure 5Ferndale and Foamix Execute License Agreement for Development of Non-Steroidal Foam for Atopic Dermatitis 2Interleukin Genetics to Present at the 13th International Conference on Periodontal Research 2Interleukin Genetics to Present at the 13th International Conference on Periodontal Research 3
(Date:7/24/2014)... work with a new drug that successfully treated lupus in ... received a $250,000 grant to expand his research to a ... a wider range of autoimmune diseases., Chandra Mohan, Hugh Roy ... UH, previously published a study in Arthritis Research & Therapy ... lupus in mice and reduced the number of cases of ...
(Date:7/24/2014)... German . The ... threats to health, and to provide life-long memory that ... underlying immunologic memory, however, has remained elusive. Since 2001, ... hypothesis that the persistence of immune memory arises from ... now, there was no conclusive evidence, largely because experiments ...
(Date:7/23/2014)... -- Pfenex Inc. (NYSE MKT: PFNX) today announced the pricing ... common stock at a price to the public of $6.00 ... 30-day option to purchase up to 1,250,000 additional shares of ... are expected to begin trading on the NYSE MKT on ... William Blair & Company, L.L.C. and JMP Securities LLC ...
Breaking Biology News(10 mins):Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3Experiments prove 'stemness' of individual immune memory cells 2Experiments prove 'stemness' of individual immune memory cells 3Pfenex Inc. Announces Pricing Of Initial Public Offering 2
... Dr. Shirley Tilghman and colleagues (Princeton University) lend new ... necessary role for a non-coding RNA transcript in the ... Imprinting, or the differential expression of a gene based ... integral to normal growth and development. Two human disorders, ...
... of predicting air pollution don't take atmospheric chlorine into ... percent or more of daily ozone production in local ... measurements taken nearly nonstop in the Irvine area over ... typically measured five parts per trillion or less, but ...
... Iron and Zinc commonly limit plant growth and crop ... to better understand the mechanisms of micronutrient uptake, distribution ... it feasible to engineer nutrient-rich plants better able to ... crop biomass in soils now in cultivation. Guerinot presented ...
Cached Biology News:UCI scientists find chlorine may contribute to ozone formation 2Metal homeostasis research in plants will lead to nutrient-rich food and higher yielding crops 2
Preparation Note: Prepared essentially by method of Singer, T.P., J. Biol. Chem., 174, 11 (1948). Quality Clarifier: Contains lipase Unit Definition: One unit will hydrolyze 1.0 μmole of p-ni...
... performance spectral scanning multimode reader with ... advanced SkanIt Software it offers superior ... assay development. Varioskan provides unlimited wavelength ... and photometric assays and a dispenser ...
... series of refrigerated cold traps offers a ... low volatility/aqueous solvents or high volatility solvents. ... vacuum concentrators/centrifugal evaporators. Also used for maintaining ... as used in electron microscopes. Can be ...
Black 96 Well Plate EB, RE Bottom...
Biology Products: